Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer

Andreas Schneeweiß, Laura L. Michel, Volker Möbus, Hans Tesch, Peter Klare, Eric Hahnen, Carsten Denkert, Karin Kast, Esther Pohl‐Rescigno, Claus Hanusch, Theresa Link, Michael Untch, Christian Jackisch, Jens‐Uwe Blohmer, Peter A. Fasching, Christine Solbach, Rita K. Schmutzler, Jens Huober, Kerstin Rhiem, Valentina Nekljudova, Kristina Lübbe, Sibylle Loibl